Can Market Sentiment Sustain UNH's Price Surge Today?

UnitedHealth stock is trading -5.56% below its average target price of $539.25 after marking a 4.7% during today's evening session. Analysts are giving the Large-Cap Medical Specialities company an average rating of buy and target prices ranging from $450.37 to $632.02 per share.

UnitedHealth's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 0.9%. The stock's short ratio is 2.2. The company's insiders own 0.24% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 89.5%. In conclusion, we believe there is mixed market sentiment regarding UnitedHealth.

Institutions Invested in UnitedHealth

Date Reported Holder Percentage Shares Value
2024-03-31 Vanguard Group Inc 9% 84,405,255 $42,984,220,985
2024-03-31 Blackrock Inc. 8% 73,670,533 $37,517,456,355
2024-03-31 State Street Corporation 5% 45,699,253 $23,272,802,029
2024-03-31 FMR, LLC 4% 35,668,357 $18,164,467,834
2024-03-31 Capital World Investors 3% 28,321,829 $14,423,174,913
2024-03-31 Price (T.Rowe) Associates Inc 3% 26,062,928 $13,272,806,967
2024-03-31 Wellington Management Group, LLP 3% 24,283,224 $12,366,474,891
2024-03-31 JP Morgan Chase & Company 3% 23,840,608 $12,141,068,262
2024-03-31 Morgan Stanley 2% 20,189,832 $10,281,874,041
2024-03-31 Geode Capital Management, LLC 2% 18,944,660 $9,647,757,736
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.